These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 8907311)

  • 1. Cross-reactivity study of low molecular weight heparins and heparinoid in heparin-induced thrombocytopenia.
    Vun CM; Evans S; Chong BH
    Thromb Res; 1996 Mar; 81(5):525-32. PubMed ID: 8907311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Heparin-associated thrombocytopenia: successful therapy of patients after prospective selection of a compatible heparinoid with the heparin-induced platelet activation test].
    Greinacher A; Michels I; Mueller-Eckhardt C
    Beitr Infusionsther; 1992; 30():408-12. PubMed ID: 1284747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparin-induced thrombocytopenia: cross-reactivity between standard heparin, low molecular weight heparin, dalteparin (Fragmin) and heparinoid, danaparoid (Orgaran).
    Ramakrishna R; Manoharan A; Kwan YL; Kyle PW
    Br J Haematol; 1995 Nov; 91(3):736-8. PubMed ID: 8555084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heparin-associated thrombocytopenia: successful therapy with the heparinoid Org 10172 in a patient showing cross-reaction to LMW heparins.
    Greinacher A; Drost W; Michels I; Leitl J; Gottsmann M; Kohl HJ; Glaser M; Mueller-Eckhardt C
    Ann Hematol; 1992 Jan; 64(1):40-2. PubMed ID: 1310879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparin-induced thrombocytopenia: IgG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low molecular weight heparin and heparinoid.
    Newman PM; Swanson RL; Chong BH
    Thromb Haemost; 1998 Aug; 80(2):292-7. PubMed ID: 9716155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet aggregation in response to four low molecular weight heparins and the heparinoid ORG 10172 in patients with heparin-induced thrombocytopenia.
    Keeling DM; Richards EM; Baglin TP
    Br J Haematol; 1994 Feb; 86(2):425-6. PubMed ID: 7515270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can low molecular weight heparins and heparinoids be safely given to patients with heparin-induced thrombocytopenia syndrome?
    Kikta MJ; Keller MP; Humphrey PW; Silver D
    Surgery; 1993 Oct; 114(4):705-10. PubMed ID: 7692613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orgaran in heparin-induced thrombocytopenia.
    Chong BH; Magnani HN
    Haemostasis; 1992; 22(2):85-91. PubMed ID: 1379968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heparin-associated thrombocytopenia: the antibody is not heparin specific.
    Greinacher A; Michels I; Mueller-Eckhardt C
    Thromb Haemost; 1992 May; 67(5):545-9. PubMed ID: 1325681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The platelet proaggregating and potentiating effects of unfractionated heparin, low molecular weight heparin and heparinoid in intensive care patients and healthy controls.
    Burgess JK; Chong BH
    Eur J Haematol; 1997 Apr; 58(4):279-85. PubMed ID: 9186540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thromboembolic complications in a patient with heparin-induced thrombocytopenia (HIT) showing cross-reactivity to a low molecular weight heparin-treatment with Org 10172 (Lomoparan).
    Muhm M; Claeys L; Huk I; Koppensteiner R; Kyrle PA; Minar E; Stümpflen A; Ehringer H; Polterauer P
    Wien Klin Wochenschr; 1997 Feb; 109(4):128-31. PubMed ID: 9076930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allergy to heparins and anticoagulants with a similar pharmacological profile: an update.
    Jappe U
    Blood Coagul Fibrinolysis; 2006 Nov; 17(8):605-13. PubMed ID: 17102645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172).
    Magnani HN
    Thromb Haemost; 1993 Oct; 70(4):554-61. PubMed ID: 7509508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delayed-type hypersensitivity to low molecular weight heparins and heparinoids: cross-reactivity does not depend on molecular weight.
    Grims RH; Weger W; Reiter H; Arbab E; Kränke B; Aberer W
    Br J Dermatol; 2007 Sep; 157(3):514-7. PubMed ID: 17573880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cross-over comparison of the anti-clotting effects of three low molecular weight heparins and glycosaminoglycuronan.
    Stiekema JC; Van Griensven JM; Van Dinther TG; Cohen AF
    Br J Clin Pharmacol; 1993 Jul; 36(1):51-6. PubMed ID: 8396956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia.
    Greinacher A; Michels I; Kiefel V; Mueller-Eckhardt C
    Thromb Haemost; 1991 Dec; 66(6):734-6. PubMed ID: 1796420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prevention of thromboembolism as a cause of thromboembolic complications. A study of the incidence of heparin-induced thrombocytopenia type II].
    Ganzer D; Gutezeit A; Mayer G; Greinacher A; Eichler P
    Z Orthop Ihre Grenzgeb; 1997; 135(6):543-9. PubMed ID: 9499523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia.
    Wilde MI; Markham A
    Drugs; 1997 Dec; 54(6):903-24. PubMed ID: 9421696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological and clinical features of low-molecular-weight heparin-induced thrombocytopenia.
    Gruel Y; Pouplard C; Nguyen P; Borg JY; Derlon A; Juhan-Vague I; Regnault V; Samama M;
    Br J Haematol; 2003 Jun; 121(5):786-92. PubMed ID: 12780795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delayed-type hypersensitivity and cross-reactivity to heparins and danaparoid: a prospective study.
    Grassegger A; Fritsch P; Reider N
    Dermatol Surg; 2001 Jan; 27(1):47-52. PubMed ID: 11231243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.